In a ghostly world

When Kazuko Shiraishi was severely ill with depression, she stopped being able to see colour – and then to taste or smell. With her senses shutting down, she longed to let go entirely.

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

09 August, 2022 Corporate Release
Lundbeck raises financial guidance range for the full year 2022
26 July, 2022 Feature
Conducting largest study ever to observe early-stage multiple system atrophy
12 July, 2022 Corporate Release
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

jason F. houston on working at Lundbeck

Advocacy Makes the Difference

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,300

employees supporting our purpose

1915

year Lundbeck was founded

No Health Without Mental Health

A Strange Dream

Out of the Silence: Speaking Up About Migraine

A messenger of hope